- Home
- CRBG vs MRNA Comparison
CRBG vs MRNA Comparison
Compare CRBG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBG
- MRNA
- Stock Information
- Founded
- CRBG 1957
- MRNA 2010
- Country
- CRBG United States
- MRNA United States
- Employees
- CRBG N/A
- MRNA N/A
- Industry
- CRBG Life Insurance
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBG Finance
- MRNA Health Care
- Exchange
- CRBG Nasdaq
- MRNA Nasdaq
- Market Cap
- CRBG 18.9B
- MRNA 16.0B
- IPO Year
- CRBG 2022
- MRNA 2018
- Fundamental
- Price
- CRBG $27.70
- MRNA $24.72
- Analyst Decision
- CRBG Buy
- MRNA Hold
- Analyst Count
- CRBG 14
- MRNA 20
- Target Price
- CRBG $36.64
- MRNA $54.47
- AVG Volume (30 Days)
- CRBG 3.7M
- MRNA 10.2M
- Earning Date
- CRBG 05-05-2025
- MRNA 05-01-2025
- Dividend Yield
- CRBG 3.46%
- MRNA N/A
- EPS Growth
- CRBG 117.54
- MRNA N/A
- EPS
- CRBG 3.72
- MRNA N/A
- Revenue
- CRBG $18,640,000,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- CRBG $18.13
- MRNA N/A
- Revenue Next Year
- CRBG $5.58
- MRNA $22.07
- P/E Ratio
- CRBG $7.45
- MRNA N/A
- Revenue Growth
- CRBG N/A
- MRNA N/A
- 52 Week Low
- CRBG $23.69
- MRNA $23.15
- 52 Week High
- CRBG $35.36
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- CRBG 42.40
- MRNA 36.68
- Support Level
- CRBG $27.03
- MRNA $23.68
- Resistance Level
- CRBG $29.26
- MRNA $27.21
- Average True Range (ATR)
- CRBG 1.78
- MRNA 2.06
- MACD
- CRBG -0.06
- MRNA -0.03
- Stochastic Oscillator
- CRBG 47.74
- MRNA 26.98
About CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments namely Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.